A phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (cc-5013) versus rituximab plus placebo in subjects with relapsed/refractory indolent lymphoma - Regional Cancer Care Associates LLC

Clinical Trials

A phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (cc-5013) versus rituximab plus placebo in subjects with relapsed/refractory indolent lymphoma

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Celgene
Protocol Number
CC-5013-NHL-007
Cancer Diagnosis
To Learn More Call
201-510-0910